AMGN · News · 20260831N

Repatha Cardiovascular Outcomes Data

AMGEN INC · 2026-08-31 · Importance 53 · Surprise 84 · In source text

Amgen reported that Repatha (evolocumab) reduced all-cause mortality risk by 20% in a Phase 3 study of more than 12,000 high-risk adults without a prior heart attack or stroke. The treatment was evaluated when added to statins or other LDL-C-lowering therapies, positioning Repatha as the first PCSK9 inhibitor shown to lower risk of death in high-risk primary-prevention patients. Global real-world analyses cited persistent lipid-management gaps, with many high-risk patients undertreated and failing to reach recommended LDL-C goals.

Key facts

Repatha reduced the risk of death by 20% in a study of more than 12,000 high-risk patients. source
Repatha reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments. source

Impact estimates

metric	direction	stage	expected	basis
revenue	positive	contingent	—	Repatha reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.